BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 27
• 28
• 29
• 30

• Bio NC

  Aldagen’s Products Isolate Human Adult Stem Cells That Can Regenerate Vascular Function; Preclinical Data Presented At The American Society Of Hematology 2005

  December 12, 2005

   · 

  1 min read
• Drug Development

  Two Leading Biotech Publications Report On Advaxis, Inc.'s Potential Treatment For Cervical Cancer

  December 12, 2005

   · 

  1 min read
• Drug Development

  Seattle Genetics, Inc. Reports SGN-40 Clinical Data At The American Society Of Hematology Annual Meeting

  December 12, 2005

   · 

  1 min read
• Drug Development

  DOV Pharmaceutical Announces Positive Futility Analysis For Pivotal Phase III Trial Of Bicifadine In Chronic Low Back Pain & Long Term Safety & Efficacy Trial Of Bicifadine Continues To Yield Encouraging Data

  December 12, 2005

   · 

  5 min read
• Policy

  FzioMed Inc. Submits Third PMA Module To The U.S. FDA For Oxiplex/SP Spine Gel

  December 12, 2005

   · 

  1 min read
• Biotech Bay

  Zeno Group: Release: New Data Suggest Novel Low-dose Outpatient Chemobiotherapy Regimen Offers Efficacy And Safety In Treating Inoperable Metastatic Melanoma

  December 12, 2005

   · 

  4 min read
• Drug Development

  American Society of Hematology Release: New Data Suggest GM-CSF May Enhance Efficacy Of Rituximab In Relapsed Follicular Lymphoma

  December 12, 2005

   · 

  4 min read
• Drug Development

  KOSAN Biosciences, Inc. Reports Interim Results Of KOS-953 Clinical Trials In Patients With Multiple Myeloma At The American Society Of Hematology Meeting

  December 12, 2005

   · 

  8 min read
• Drug Development

  Targepeutics, Inc. Announces New Approaches To Brain Tumor Therapy Consortium (NABTT) Relationship

  December 12, 2005

   · 

  1 min read
• Drug Development

  Novartis Pharmaceuticals Corporation Release: More Than 90% Of Patients Taking Gleevec(R) For A Form Of Chronic Myeloid Leukemia (CML) Alive After 4-1/2 Years In Landmark Study

  December 12, 2005

   · 

  10 min read